Advertisement

Monoamine Transporter and Receptor Interaction Profiles of Synthetic Cathinones

  • Linda D. Simmler
Chapter
Part of the Current Topics in Neurotoxicity book series (Current Topics Neurotoxicity, volume 12)

Abstract

Cathinones are amphetamine-type substances with a β-keto substitution, typically emerging as drugs of abuse among novel psychoactive substances (NPS). In vitro screenings have been useful in characterizing pharmacological profiles of cathinone NPS and in obtaining fast estimates of mechanisms of action, potencies, and potential toxicity. Pharmacological targets of cathinone psychostimulants are dopamine, serotonin, and noradrenaline re-uptake transporters (DAT, SERT, and NET, respectively), as well as monoamine receptors. However, there are considerable differences among cathinones with respect to potencies and relative activity at monoaminergic targets. Foremost, cathinones act on NET, DAT, and/or SERT as inhibitors, usually also inducing reverse transport of monoamines. For many cathinones, it is difficult to predict pharmacological profiles, and consequently to anticipate acute effects, doses, and toxicity, based solely on their chemical structures. In vitro screening and pharmacological classification are therefore essential in providing translationally valuable information promptly after new cathinone derivatives emerge among drug users. This chapter provides an overview of the pharmacological profiles of NPS cathinones, which have been characterized in in vitro screenings.

Keywords

Affinity Cathinone DAT Dopamine NET Noradrenaline Monoamines Pharmacological profiles Release Serotonin SERT Synthetic cathinones Uptake 

Notes

Acknowledgements

The author would like to thank Dr. Shannon L. Wolfman for proofreading the manuscript. The author is supported by the Swiss National Science Foundation (PZ00P3_174178).

References

  1. Aarde SM, Taffe MA (2017) Predicting the abuse liability of entactogen-class, new and emerging psychoactive substances via preclinical models of drug self-administration. Curr Top Behav Neurosci 32:145–164.  https://doi.org/10.1007/7854_2016_54CrossRefPubMedGoogle Scholar
  2. Barker EL, Blakely RD (1996) Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol 50(4):957–965PubMedGoogle Scholar
  3. Bauer CT, Banks ML, Blough BE, Negus SS (2013) Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Br J Pharmacol 168(4):850–862.  https://doi.org/10.1111/j.1476-5381.2012.02214.xCrossRefPubMedPubMedCentralGoogle Scholar
  4. Baumann MH, Ayestas MA Jr, Partilla JS et al (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37(5):1192–1203.  https://doi.org/10.1038/npp.2011.304CrossRefPubMedGoogle Scholar
  5. Baumann MH, Bukhari MO, Lehner KR et al (2017) Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs. Curr Top Behav Neurosci 32:93–117.  https://doi.org/10.1007/7854_2016_53CrossRefPubMedPubMedCentralGoogle Scholar
  6. Blakely RD, Defelice LJ, Galli A (2005) Biogenic amine neurotransmitter transporters: just when you thought you knew them. Physiology 20:225–231.  https://doi.org/10.1152/physiol.00013.2005CrossRefPubMedGoogle Scholar
  7. Bradaia A, Trube G, Stalder H et al (2009) The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A 106(47):20081–20086.  https://doi.org/10.1073/pnas.0906522106CrossRefPubMedPubMedCentralGoogle Scholar
  8. Burlingham BT, Widlanski TS (2003) An intuitive look at the relationship of K-i and IC50: a more general use for the Dixon plot. J Chem Educ 80(2):214–218CrossRefGoogle Scholar
  9. Daw ND, Kakade S, Dayan P (2002) Opponent interactions between serotonin and dopamine. Neural Net 15(4–6):603–616CrossRefGoogle Scholar
  10. de la Torre R, Farre M, Roset PN et al (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26(2):137–144CrossRefGoogle Scholar
  11. EMCDDA (2016) European drug report 2016. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Luxembourg.  https://doi.org/10.2810/084165
  12. Eshleman AJ, Wolfrum KM, Hatfield MG et al (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmac 85(12):1803–1815.  https://doi.org/10.1016/j.bcp.2013.04.004CrossRefGoogle Scholar
  13. Eshleman AJ, Wolfrum KM, Reed JF et al (2017) Structure-activity relationships of substituted cathinones, with transporter binding, uptake, and release. J Pharmacol Exp Ther 360(1):33–47.  https://doi.org/10.1124/jpet.116.236349CrossRefPubMedPubMedCentralGoogle Scholar
  14. Green AR, King MV, Shortall SE, Fone KC (2014) The preclinical pharmacology of mephedrone; not just MDMA by another name. Br J Pharmacol 171(9):2251–2268.  https://doi.org/10.1111/bph.12628CrossRefPubMedPubMedCentralGoogle Scholar
  15. Gregg RA, Baumann MH, Partilla JS et al (2015) Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. Br J Pharmacol 172(3):883–894.  https://doi.org/10.1111/bph.12951CrossRefPubMedGoogle Scholar
  16. Han DD, Gu HH (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6:6.  https://doi.org/10.1186/1471-2210-6-6CrossRefPubMedPubMedCentralGoogle Scholar
  17. Hysek CM, Simmler LD, Ineichen M et al (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther 90(2):246–255.  https://doi.org/10.1038/clpt.2011.78CrossRefPubMedGoogle Scholar
  18. Hysek CM, Simmler LD, Nicola VG et al (2012) Duloxetine inhibits effects of MDMA (“Ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS ONE 7(5):e36476.  https://doi.org/10.1371/journal.pone.0036476CrossRefPubMedPubMedCentralGoogle Scholar
  19. Hysek CM, Fink AE, Simmler LD et al (2013) α1-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans. J Clin Psychopharmacol 33(5):658–666.  https://doi.org/10.1097/JCP.0b013e3182979d32CrossRefPubMedGoogle Scholar
  20. Iversen L, Gibbons S, Treble R et al (2013) Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 700(1–3):147–151.  https://doi.org/10.1016/j.ejphar.2012.12.006CrossRefPubMedGoogle Scholar
  21. Kraehenmann R, Pokorny D, Vollenweider L et al (2017) Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology 234(13):2031–2046.  https://doi.org/10.1007/s00213-017-4610-0CrossRefPubMedGoogle Scholar
  22. Liechti M (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly 145:w14043.  https://doi.org/10.4414/smw.2015.14043CrossRefPubMedGoogle Scholar
  23. Liechti ME, Vollenweider FX (2001) Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 16(8):589–598.  https://doi.org/10.1002/hup.348CrossRefPubMedGoogle Scholar
  24. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000a) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22(5):513–521.  https://doi.org/10.1016/S0893-133X(99)00148-7CrossRefPubMedGoogle Scholar
  25. Liechti ME, Saur MR, Gamma A et al (2000b) Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23(4):396–404.  https://doi.org/10.1016/S0893-133X(00)00126-3CrossRefPubMedGoogle Scholar
  26. Luethi D, Kolaczynska KE, Docci L et al (2017) Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology.  https://doi.org/10.1016/j.neuropharm.2017.07.026CrossRefPubMedGoogle Scholar
  27. Luscher C, Malenka RC (2011) Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69(4):650–663.  https://doi.org/10.1016/j.neuron.2011.01.017CrossRefPubMedPubMedCentralGoogle Scholar
  28. Meltzer PC, Butler D, Deschamps JR, Madras BK (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49(4):1420–1432.  https://doi.org/10.1021/jm050797aCrossRefPubMedPubMedCentralGoogle Scholar
  29. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131–181.  https://doi.org/10.1016/j.pharmthera.2003.11.002CrossRefPubMedGoogle Scholar
  30. Nickell JR, Siripurapu KB, Vartak A et al (2014) The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol 69:71–106.  https://doi.org/10.1016/B978-0-12-420118-7.00002-0CrossRefPubMedPubMedCentralGoogle Scholar
  31. Preller KH, Herdener M, Pokorny T et al (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Current Biol 27(3):451–457.  https://doi.org/10.1016/j.cub.2016.12.030CrossRefGoogle Scholar
  32. Revel FG, Meyer CA, Bradaia A et al (2012) Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology 37(12):2580–2592.  https://doi.org/10.1038/npp.2012.109CrossRefPubMedPubMedCentralGoogle Scholar
  33. Rickli A, Hoener MC, Liechti ME (2015) Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 25(3):365–376.  https://doi.org/10.1016/j.euroneuro.2014.12.012CrossRefPubMedGoogle Scholar
  34. Rothman RB, Baumann MH, Dersch CM et al (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39(1):32–41. https://doi.org/10.1002/1098-2396(20010101)39:1<32:AID-SYN5>3.0.CO;2-3Google Scholar
  35. Saha K, Partilla JS, Lehner KR et al (2015) ‘Second-generation’ mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacology 40(6):1321–1331.  https://doi.org/10.1038/npp.2014.325CrossRefPubMedPubMedCentralGoogle Scholar
  36. Schmid Y, Enzler F, Gasser P et al (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78(8):544–553.  https://doi.org/10.1016/j.biopsych.2014.11.015CrossRefPubMedGoogle Scholar
  37. Scholze P, Zwach J, Kattinger A et al (2000) Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther 293(3):870–878PubMedGoogle Scholar
  38. Shalabi AR, Walther D, Baumann MH, Glennon RA (2017) Deconstructed analogues of bupropion reveal structural requirements for transporter inhibition versus substrate-induced neurotransmitter release. ACS Chem Neurosci 8(6):1397–1403.  https://doi.org/10.1021/acschemneuro.7b00055CrossRefPubMedGoogle Scholar
  39. Simmler LD, Liechti ME (2017) Interactions of cathinone NPS with human transporters and receptors in transfected cells. Curr Top Behav Neurosci 32:49–72.  https://doi.org/10.1007/7854_2016_20CrossRefPubMedGoogle Scholar
  40. Simmler L, Buser T, Donzelli M et al (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168(2):458–470.  https://doi.org/10.1111/j.1476-5381.2012.02145.xCrossRefPubMedGoogle Scholar
  41. Simmler LD, Rickli A, Hoener MC, Liechti ME (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79:152–160.  https://doi.org/10.1016/j.neuropharm.2013.11.008CrossRefPubMedGoogle Scholar
  42. Simmler LD, Buchy D, Chaboz S et al (2016) In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. J Pharmacol Exp Ther 357(1):134–144.  https://doi.org/10.1124/jpet.115.229765CrossRefPubMedGoogle Scholar
  43. Wee S, Anderson KG, Baumann MH et al (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313(2):848–854.  https://doi.org/10.1124/jpet.104.080101CrossRefPubMedGoogle Scholar
  44. White CM (2016) Mephedrone and 3,4-methylenedioxypyrovalerone (MDPV): synthetic cathinones with serious health implications. J Clin Pharmacol 56(11):1319–1325.  https://doi.org/10.1002/jcph.742CrossRefPubMedGoogle Scholar
  45. Zawilska JB, Wojcieszak J (2017) α-Pyrrolidinophenones: a new wave of designer cathinones. Forensic Toxicol 35(2):201–216.  https://doi.org/10.1007/s11419-016-0353-6CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Basic NeurosciencesUniversity of GenevaGenevaSwitzerland

Personalised recommendations